Holen Sie sich die Stockscreener-App
10.50
0.57%
-0.06
Handel nachbörslich:
10.50
Alvotech Aktie (ALVO) Neueste Nachrichten
Alvotech at BofA Securities Healthcare Conference: Strategic Biosimilar Focus By Investing.com - Investing.com India
Alvogen Lux Holdings Acquires 210,000 Shares in Alvotech at ISK 1,277.38 - Nasdaq
Transactions of Managers and Closely Associated Persons - marketscreener.com
Alvotech Raises 2025 Revenue Guidance Amid Strong Performance - TipRanks
Teva, Alvotech receive FDA nod for interchangeability of Selardsdi with Stelara - Drug Store News
Analyst Estimates: Here's What Brokers Think Of Alvotech (NASDAQ:ALVO) After Its First-Quarter Report - Yahoo Finance
Alvotech CEO Acquires Significant Shareholding, Strengthening Market Confidence - TipRanks
Is Alvotech (ALVO) The Best Stock That Will Bounce Back? - Insider Monkey
Alvotech Meets Investors and Participates in Fireside Chat At the BofA Securities Healthcare Conference 2025 in Las Vegas, Nevada - The Manila Times
Alvotech Reports Strong Q1 2025 Earnings Growth - TipRanks
Alvotech earnings beat by $0.32, revenue topped estimates - Investing.com Nigeria
Alvotech sees minimal impact on 2025 product revenues from tariffs - MSN
Transcript : Alvotech, Q1 2025 Earnings Call, May 08, 2025 - marketscreener.com
Groupon Posts Upbeat Earnings, Joins Axon Enterprise, Warner Bros. Discovery, MercadoLibre And Other Big Stocks Moving Higher On Thursday - Benzinga
Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT - marketscreener.com
Alvotech Reports Robust Q1 2025 Growth and Strategic Expansions - TipRanks
ACM Research Reports First Quarter 2025 Results - Stock Titan
Alvotech Publishes Prospectus in Connection with its Listing on Nasdaq Stockholm - The Manila Times
Alvotech Q1 2025 Earnings Call Transcript - MarketBeat
Alvotech (NASDAQ:ALVO) Sees Significant Growth in Short Interest - MarketBeat
Alvotech shares surge 6.6% as Q1 results top estimates By Investing.com - Investing.com Nigeria
Alvotech shares surge 6.6% as Q1 results top estimates - Investing.com
Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update - The Manila Times
Alvotech Anticipates Minimal Impact from Potential U.S. Tariffs on Imported Pharmaceuticals in 2025 - Nasdaq
Alvotech Sees Minimal Impact On 2025 Revenues From U.S. Tariffs - marketscreener.com
Alvotech : Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech's Product Revenues in 2025 - marketscreener.com
Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech's Product Revenues in 2025 - The Manila Times
Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech’s Product Revenues in 2025 - Yahoo Home
Teva, Alvotech get FDA nod for Johnson & Johnson biosimilar - MSN
Teva And Alvotech Celebrate Interchangeability For US Ustekinumab - insights.citeline.com
FDA approves Teva-Alvotech biosimilar Selarsdi for multiple conditions - World Pharmaceutical Frontiers
Alvotech SA expected to post a loss of 11 cents a shareEarnings Preview - TradingView
FDA Approves SELARSDI from Alvotech (ALVO) as Interchangeable Bi - GuruFocus
Why Is Israel-Based Generic Drug Focused Teva Pharmaceutical Stock Trading Higher On Monday? - Benzinga
Teva, Alvotech announce FDA approval of interchangeability for SELARSDI - TipRanks
US FDA Approves Alvotech's Selarsdi for Full Interchangeability with J&J's Stelara - marketscreener.com
Teva and Alvotech stocks jump on FDA approval of SELARSDI By Investing.com - Investing.com Nigeria
Teva and Alvotech stocks jump on FDA approval of SELARSDI - Investing.com Australia
Teva, Alvotech: FDA approves interchangeability for SELARSDI with Stelara - TipRanks
Alvotech’s SELARSDI Gains FDA Approval for Interchangeability with Stelara - TipRanks
Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab) | TEVA Stock News - GuruFocus
Teva, Alvotech Get FDA Approval for Selarsdi's Interchangeablity With Stelara - marketscreener.com
Teva and Alvotech Announce FDA Approval of - GlobeNewswire
Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab) - finanzen.ch
FDA Grants Full Interchangeability to New Stelara Biosimilar for Multiple Autoimmune Conditions - Stock Titan
FDA Approval Boosts Alvotech's (ALVO) SELARSDI as Interchangeabl - GuruFocus
Alvotech to Announce Q1 2025 Financial Results on May 7, 2025, with Conference Call on May 8, 2025 - Nasdaq
Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT (14:00 CET) - The Manila Times
Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT (14 - marketscreener.com
REG-Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT (14:00 CET) - TradingView
0.18%
0.28%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):